<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Lamivudine/Zidovudine Teva, INN-lamivudine/zidovudine</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char1";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char1";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char1";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char1";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char1";
	margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char1";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char1";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char1";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char1";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char1";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.05pt;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char1";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char1";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char1";
	margin:0in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{font-family:"Times New Roman",serif;
	color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char1";
	margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char1";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
span.Heading1Char1
	{mso-style-name:"Heading 1 Char1";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading2Char1
	{mso-style-name:"Heading 2 Char1";
	mso-style-link:"Heading 2";
	font-family:"Cambria",serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char1
	{mso-style-name:"Heading 3 Char1";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading4Char1
	{mso-style-name:"Heading 4 Char1";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading5Char1
	{mso-style-name:"Heading 5 Char1";
	mso-style-link:"Heading 5";
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading6Char1
	{mso-style-name:"Heading 6 Char1";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading7Char1
	{mso-style-name:"Heading 7 Char1";
	mso-style-link:"Heading 7";
	font-family:"Calibri",sans-serif;}
span.Heading8Char1
	{mso-style-name:"Heading 8 Char1";
	mso-style-link:"Heading 8";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.Heading9Char1
	{mso-style-name:"Heading 9 Char1";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HeaderChar1
	{mso-style-name:"Header Char1";
	mso-style-link:Header;}
span.FooterChar1
	{mso-style-name:"Footer Char1";
	mso-style-link:Footer;}
span.BodyTextIndentChar1
	{mso-style-name:"Body Text Indent Char1";
	mso-style-link:"Body Text Indent";}
span.BodyText3Char1
	{mso-style-name:"Body Text 3 Char1";
	mso-style-link:"Body Text 3";}
span.BodyTextIndent2Char1
	{mso-style-name:"Body Text Indent 2 Char1";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextChar1
	{mso-style-name:"Body Text Char1";
	mso-style-link:"Body Text";}
span.BodyText2Char1
	{mso-style-name:"Body Text 2 Char1";
	mso-style-link:"Body Text 2";}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";
	mso-style-link:"Comment Text";}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar1
	{mso-style-name:"Document Map Char1";
	mso-style-link:"Document Map";}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
span.BodyTextIndent3Char1
	{mso-style-name:"Body Text Indent 3 Char1";
	mso-style-link:"Body Text Indent 3";}
span.BalloonTextChar1
	{mso-style-name:"Balloon Text Char1";
	mso-style-link:"Balloon Text";}
p.CM26, li.CM26, div.CM26
	{mso-style-name:CM26;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.9pt;
	margin-left:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CM5, li.CM5, div.CM5
	{mso-style-name:CM5;
	margin:0in;
	line-height:12.8pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CM3, li.CM3, div.CM3
	{mso-style-name:CM3;
	margin:0in;
	line-height:12.8pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CM27, li.CM27, div.CM27
	{mso-style-name:CM27;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:25.9pt;
	margin-left:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:normal;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.CM10, li.CM10, div.CM10
	{mso-style-name:CM10;
	margin:0in;
	line-height:13.0pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CM6, li.CM6, div.CM6
	{mso-style-name:CM6;
	margin:0in;
	line-height:12.9pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	line-height:normal;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.tabletextNS, li.tabletextNS, div.tabletextNS
	{mso-style-name:"table\:textNS";
	mso-style-link:"table\:textNS Char";
	margin:0in;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.tabletextNSChar
	{mso-style-name:"table\:textNS Char";
	mso-style-link:"table\:textNS";
	font-family:"Arial Narrow",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	font-family:"Times New Roman",serif;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
span.HeaderChar
	{mso-style-name:"Header Char";
	font-family:"Helvetica",sans-serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	font-family:"Helvetica",sans-serif;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	font-family:"Times New Roman",serif;
	color:blue;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	font-family:"Tahoma",sans-serif;}
p.Revision1, li.Revision1, div.Revision1
	{mso-style-name:Revision1;
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.ListParagraph1, li.ListParagraph1, div.ListParagraph1
	{mso-style-name:"List Paragraph1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	mso-style-link:"Title B Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.TitleBChar
	{mso-style-name:"Title B Char";
	mso-style-link:"Title B";
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b>ANNEX
I</b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lamivudine/Zidovudine Teva</span><span lang=EN-GB
style='font-family:"Arial",sans-serif;color:black'> </span><span lang=EN-GB>150&nbsp;mg/300&nbsp;mg
film-coated tablets</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film-coated
tablet contains 150&nbsp;mg lamivudine and 300&nbsp;mg zidovudine. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients see section 6.1. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film-coated tablet</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>White, capsule shaped, biconvex,
film-coated scored tablet &#8211; engraved with &#8220;L/Z&#8221; on one side
and &#8220;150/300&#8221; on the other side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The tablet can be divided into equal
halves.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span lang=EN-GB> is indicated in antiretroviral combination therapy
for the treatment of Human Immunodeficiency Virus (HIV) infection (see section
4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Therapy should be initiated by a physician
experienced in the management of HIV infection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span lang=EN-GB> may be administered with or without food. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>To ensure administration of the entire
dose, the tablet(s) should ideally be swallowed without crushing. For patients
who are unable to swallow tablets, tablets may be crushed and added to a small
amount of semi-solid food or liquid, all of which should be consumed
immediately (see section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Adults and adolescents weighing at least
30&nbsp; kg:</span></i><span lang=EN-GB> the recommended oral dose of <span
style='color:black'>Lamivudine/Zidovudine Teva</span> is one tablet twice
daily. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Children weighing between 21&nbsp;kg and
30&nbsp;kg: the recommended oral dose of Lamivudine/Zidovudine Teva is one-half
tablet taken in the morning and one whole tablet taken in the evening. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Children weighing from 14&nbsp;kg to
21&nbsp;kg:</span></i><span lang=EN-GB> the recommended oral dose of <span
style='color:black'>Lamivudine/Zidovudine Teva</span> is one-half tablet taken
twice daily. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The dosing regimen for paediatric patients
weighing 14&#8209;30&nbsp;kg is based primarily on pharmacokinetic modelling
and supported by data from clinical studies using the individual components
lamivudine and zidovudine. A pharmacokinetic overexposure of zidovudine can
occur, therefore close safety monitoring is warranted in these patients. If
gastrointestinal intolerance occurs in patients weighing 21&#8209;30&nbsp;kg,
an alternative dosing schedule with one-half tablet taken thrice daily can be
applied in attempt to improve tolerability. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span lang=EN-GB> tablets should not be used for children weighing
less than 14&nbsp;kg, since doses cannot be appropriately adjusted for the
weight of the child. In these patients, lamivudine and zidovudine should be
taken as separate formulations according to the prescribed dosing recommendations
for these products. For these patients and for patients, who are unable to
swallow tablets, oral solutions of lamivudine and zidovudine are available. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For situations where discontinuation of
therapy with one of the active substances of <span style='color:black'>Lamivudine/Zidovudine
Teva</span>, or dose reduction is necessary, separate preparations of
lamivudine and zidovudine are available in tablets/capsules and oral solution.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Renal impairment</span></i><b><span
lang=EN-GB>:</span></b><span lang=EN-GB> Lamivudine and zidovudine
concentrations are increased in patients with renal impairment due to decreased
clearance. Therefore as dosage adjustment of these may be necessary it is
recommended that separate preparations of lamivudine and zidovudine be
administered to patients with reduced renal function (creatinine clearance
&#8804;50&nbsp;ml/min). Physicians should refer to the individual prescribing
information for these medicinal products. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment: </span></i><span
lang=EN-GB>Limited data in patients with cirrhosis suggest that accumulation of
zidovudine may occur in patients with hepatic impairment because of decreased
glucuronidation. Data obtained in patients with moderate to severe hepatic
impairment show that lamivudine pharmacokinetics are not significantly affected
by hepatic dysfunction. However, as dosage adjustments for zidovudine may be
necessary, it is recommended that separate preparations of lamivudine and
zidovudine be administered to patients with severe hepatic impairment. Physicians
should refer to the individual prescribing information for these medicinal
products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Dosage adjustments in patients with
haematological adverse reactions: </span></i><span lang=EN-GB>Dosage adjustment
of zidovudine may be necessary if the haemoglobin level falls below 9&nbsp;g/dl
or 5.59&nbsp;mmol/l or the neutrophil count falls below 1.0&nbsp;x&nbsp;10<sup>9</sup>/l
(see sections 4.3 and 4.4). As dosage adjustment of <span style='color:black'>Lamivudine/Zidovudine
Teva</span> is not possible, separate preparations of zidovudine and lamivudine
should be used. Physicians should refer to the individual prescribing
information for these medicinal products. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Dosage in the elderly: </span></i><span
lang=EN-GB>No specific data are available, however special care is advised in
this age group due to age associated changes such as the decrease in renal
function and alteration of haematological parameters. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to the active substances
or to any of the excipients <span style='color:black'>listed in section 6.1</span>.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Zidovudine is contraindicated in patients
with abnormally low neutrophil counts (&lt;0.75&nbsp;x&nbsp;10<sup>9</sup>/l),
or abnormally low haemoglobin levels (&lt;7.5&nbsp;g/dl or 4.65&nbsp;mmol/l). <span
style='color:black'>Lamivudine/Zidovudine Teva</span> is therefore
contraindicated in these patients (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While effective viral suppression with
antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The special warnings and precautions
relevant to both lamivudine and zidovudine are included in this section. There
are no additional precautions and warnings relevant to the combination <span
style='color:black'>Lamivudine/Zidovudine Teva</span>. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that separate
preparations of lamivudine and zidovudine should be administered in cases where
dosage adjustment is necessary (see section 4.2). In these cases the physician
should refer to the individual prescribing information for these medicinal
products. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The concomitant use of stavudine with
zidovudine should be avoided (see section 4.5). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Opportunistic infections:</span></i><span
lang=EN-GB> Patients receiving <span style='color:black'>Lamivudine/Zidovudine
Teva</span> or any other antiretroviral therapy may continue to develop
opportunistic infections and other complications of HIV infection. Therefore
patients should remain under close clinical observation by physicians
experienced in the treatment of HIV infection. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Haematological adverse reactions: </span></i><span
lang=EN-GB>Anaemia, neutropenia and leucopenia (usually secondary to
neutropenia) can be expected to occur in patients receiving zidovudine. These
occurred more frequently at higher zidovudine dosages (1200&#8209;1500&nbsp;mg/day)
and in patients with poor bone marrow reserve prior to treatment, particularly
with advanced HIV disease. Haematological parameters should therefore be
carefully monitored (see section 4.3) in patients receiving <span
style='color:black'>Lamivudine/Zidovudine Teva</span>. These haematological
effects are not usually observed before four to six weeks therapy. For patients
with advanced symptomatic HIV disease, it is generally recommended that blood
tests are performed at least every two weeks for the first three months of
therapy and at least monthly thereafter. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with early HIV disease
haematological adverse reactions are infrequent. Depending on the overall
condition of the patient, blood tests may be performed less often, for example
every one to three months. Additionally dosage adjustment of zidovudine may be
required if severe anaemia or myelosuppression occurs during treatment with <span
style='color:black'>Lamivudine/Zidovudine Teva,</span> or in patients with
pre-existing bone marrow compromise e.g. haemoglobin &lt;9&nbsp;g/dl
(5.59&nbsp;mmol/l) or neutrophil count &lt;1.0&nbsp;x&nbsp;10<sup><span
style='position:relative;top:-5.0pt'>9</span></sup>/l (see section 4.2). As
dosage adjustment of <span style='color:black'>Lamivudine/Zidovudine Teva</span>
is not possible separate preparations of zidovudine and lamivudine should be
used. Physicians should refer to the individual prescribing information for
these medicinal products. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Pancreatitis:</span></i><span
lang=EN-GB> Cases of pancreatitis have occurred rarely in patients treated with
lamivudine and zidovudine. However it is not clear whether these cases were due
to the antiretroviral treatment or to the underlying HIV disease. Treatment
with <span style='color:black'>Lamivudine/Zidovudine Teva</span> should be
stopped immediately if clinical signs, symptoms or laboratory abnormalities
suggestive of pancreatitis occur. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><i><span lang=EN-GB>Lactic
acidosis: </span></i><span lang=EN-GB>Lactic acidosis usually associated with
hepatomegaly and hepatic steatosis has been reported with the use of zidovudine.
Early symptoms (symptomatic hyperlactatemia) include benign digestive symptoms
(nausea, vomiting and abdominal pain) non-specific malaise, loss of appetite,
weight loss, respiratory symptoms (rapid and/or deep breathing) or neurological
symptoms (including motor weakness). </span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Lactic
acidosis has a high mortality and may be associated with pancreatitis, liver
failure, or renal failure. </span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Lactic
acidosis generally occurred after a few or several months of treatment. </span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Treatment
with zidovudine should be discontinued if there is symptomatic hyperlactatemia
and metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating
aminotransferase levels.</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Caution
should be exercised when administering zidovudine to any patient (particularly
obese women) with hepatomegaly, hepatitis or other known risk factors for liver
disease and hepatic steatosis (including certain medicinal products and
alcohol). Patients co-infected with hepatitis C and treated with alpha
interferon and ribavirin may constitute a special risk.</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Patients at
increased risk should be followed closely.</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Mitochondrial dysfunction</span></i><i><span
lang=EN-GB> following exposure in utero:</span></i><span lang=EN-GB> Nucleoside
and nucleotide analogues</span><span lang=EN-GB> </span><span lang=EN-GB>may
impact mitochondrial function to a variable degree, which is most pronounced
with stavudine, didanosine and zidovudine. There have been reports of
mitochondrial dysfunction in HIV-negative infants exposed <i>in utero</i>
and/or post-natally to nucleoside analogues; these have predominantly concerned
treatment with regimens containing zidovudine. The main adverse reactions
reported are haematological disorders (anaemia, neutropenia) and metabolic
disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory.
Late-onset neurological disorders have been reported rarely (hypertonia,
convulsion, abnormal behaviour). Whether such neurological disorders are
transient or permanent is currently unknown. These findings should be
considered for any child exposed <i>in utero</i> to nucleoside and nucleotide
analogues, who presents with severe clinical findings of unknown etiology
particularly neurologic findings. These findings do not affect current national
recommendations to use antiretroviral therapy in pregnant women to prevent
vertical transmission of HIV. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Lipoatrophy:</span></i><span
lang=EN-GB> </span><span style='color:black;layout-grid-mode:line'>Treatment
with zidovudine has been associated with loss of subcutaneous fat, which has
been linked to mitochondrial toxicity. The incidence and severity of
lipoatrophy are related to cumulative exposure. This fat loss, which is most
evident in the face, limbs and buttocks, may not be reversible when switching
to a zidovudine-free regimen. Patients should be regularly assessed for signs
of lipoatrophy during therapy with zidovudine and zidovudine-containing products.
Therapy should be switched to an alternative regimen if there is suspicion of
lipoatrophy development.</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black;layout-grid-mode:line'>Weight
and metabolic parameters: </span></i><span style='color:black;layout-grid-mode:
line'>An increase in weight and in levels of blood lipids and glucose may occur
during antiretroviral therapy. Such changes may in part be linked to disease
control and life style. For lipids, there is in some cases evidence for a
treatment effect, while for weight gain there is no strong evidence relating
this to any particular treatment. For monitoring of blood lipids and glucose
reference is made to established HIV treatment guidelines. Lipid disorders
should be managed as clinically appropriate</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Immune Reactivation Syndrome:</span></i><span
lang=EN-GB> In HIV-infected patients with severe immune deficiency at the time
of institution of combination antiretroviral therapy (CART), an inflammatory
reaction to asymptomatic or residual opportunistic pathogens may arise and
cause serious clinical conditions, or aggravation of symptoms. Typically, such
reactions have been observed within the first few weeks or months of initiation
of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or
focal mycobacterium infections, and <i>Pneumocystis jirovecii pneumonia (often
referred to as PCP)</i>. Any inflammatory symptoms should be evaluated and
treatment instituted when necessary. Autoimmune disorders (such as
Graves&#8217; disease and autoimmune hepatitis) have also been reported to
occur in the setting of immune reactivation; however, the reported time to
onset is more variable and these events can occur many months after initiation
of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Liver disease: </span></i><span
lang=EN-GB>If lamivudine is being used concomitantly for the treatment of HIV
and HBV, additional information relating to the use of lamivudine in the
treatment of hepatitis B infection is available in the lamivudine 100&nbsp;mg SmPC.
</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety and efficacy of zidovudine has
not been established in patients with significant underlying liver disorders. </span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with chronic hepatitis B or C and
treated with combination antiretroviral therapy are at an increased risk of
severe and potentially fatal hepatic adverse events. In case of concomitant
antiviral therapy for hepatitis B or C, please refer also to the relevant
product information for these medicinal products. </span></p>

<p class=MsoNormal><span lang=EN-GB>If <span style='color:black'>Lamivudine/Zidovudine
Teva</span> is discontinued in patients co-infected with hepatitis B virus,
periodic monitoring of both liver function tests and markers of HBV replication
for 4 months is recommended, as withdrawal of lamivudine may result in an acute
exacerbation of hepatitis. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with pre-existing liver
dysfunction, including chronic active hepatitis, have an increased frequency of
liver function abnormalities during combination antiretroviral therapy, and
should be monitored according to standard practice. If there is evidence of
worsening liver disease in such patients, interruption or discontinuation of
treatment must be considered. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Patients co-infected with hepatitis C
virus:</span></i><span lang=EN-GB> The concomitant use of ribavirin with
zidovudine is not recommended due to an increased risk of anaemia (see section
4.5). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Osteonecrosis</span></i><span
lang=EN-GB>: Although the etiology is considered to be multifactorial
(including corticosteroid use, alcohol consumption, severe immunosuppression,
higher body mass index), cases of osteonecrosis have been reported particularly
in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral
therapy (CART). Patients should be advised to seek medical advice if they
experience joint aches and pain, joint stiffness or difficulty in movement. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine/Zidovudine Teva should not be
taken with any other medicinal products containing lamivudine or medicinal
products containing emtricitabine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The combination of lamivudine with
cladribine is not recommended (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Excipient(s)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Sodium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span style='color:black'> contains lamivudine and zidovudine, </span><span
style='color:black'>therefore </span><span style='color:black'>any interactions
identified </span><span style='color:black'>for</span><span style='color:black'>
these individually </span><span style='color:black'>are relevant to</span><span
style='color:black'> Lamivudine/Zidovudine Teva. </span><span style='color:
black'>Clinical studies have shown that there are no clinically significant</span><span
style='color:black'> interactions </span><span style='color:black'>between</span><span
style='color:black'> lamivudine and </span><span style='color:black'>zidovudine.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Zidovudine is primarily metabolised by UGT
enzymes; co-administration of inducers or inhibitors of UGT enzymes could alter
zidovudine exposure. Lamivudine is cleared renally. Active renal secretion of
lamivudine in the urine is mediated through organic cation transporters (OCTs);
co-administration of lamivudine with OCT inhibitors or nephrotoxic drugs may
increase lamivudine exposure.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>Lamivudine and
zidovudine are not significantly metabolised by cytochrome P<sub><span
style='color:black'>450</span></sub> enzymes (such as </span><span
style='color:black'>CYP 3A4, CYP 2C9 or CYP 2D6) </span><span style='layout-grid-mode:
line'>nor do they inhibit or induce this enzyme system. </span><span
style='color:black'>Therefore, there is little potential for interactions with
antiretroviral protease inhibitors, non-nucleosides and other medicinal
products metabolised by major P<sub>450</sub> enzymes.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal>Interaction studies have only been performed in adults. The
list below should not be considered exhaustive but is representative of the classes
studied. </p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Drugs by
  Therapeutic Area</span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Interaction<br>
  Geometric mean change (%)</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>(Possible
  mechanism)</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.64%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Recommendation
  concerning co-administration</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ANTIRETROVIRAL
  MEDICINAL PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Didanosine/Lamivudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Interaction not
  studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>No dosage adjustment
  necessary.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Didanosine</span><span
  lang=EN-GB> /Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Interaction not
  studied.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Stavudine/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Interaction not
  studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Combination not
  recommended.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Stavudine/Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>In vitro
  antagonism of anti-HIV activity between stavudine and zidovudine could result
  in decreased efficacy of both drugs.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>ANTI-INFECTIVE
  PRODUCTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Atovaquone/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As only
  limited data available the clinical significance is unknown.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Atovaquone/Zidovudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;(750&nbsp;mg
  twice daily with food/200&nbsp;mg thrice daily)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&shy;</span><span
  lang=EN-GB>33%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Atovaquone AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&laquo;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clarithromycin/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Separate
  administration of Lamivudine/Zidovudine Teva and clarithromycin by at least
  2&nbsp;hours</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clarithromycin/Zidovudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(500&nbsp;mg
  twice daily/100&nbsp;mg every 4&nbsp;hours)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&macr;</span><span
  lang=EN-GB>12%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trimethoprim/sulfamethoxazole</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(Co-trimoxazole)/Lamivudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(160&nbsp;mg/800&nbsp;mg
  once daily for 5 days/</span><span lang=IT>300&nbsp;mg single dose)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Lamivudine: AUC </span><span
  lang=EN-GB style='font-family:Symbol;color:black;layout-grid-mode:line'>&shy;</span><span
  lang=EN-GB style='color:black;layout-grid-mode:line'>40%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Trimethoprim: AUC </span><span
  lang=EN-GB style='font-family:Symbol;color:black;layout-grid-mode:line'>&laquo;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Sulfamethoxazole: AUC </span><span
  lang=EN-GB style='font-family:Symbol;color:black;layout-grid-mode:line'>&laquo;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>(organic cation transporter
  inhibition)</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>No Lamivudine/Zidovudine Teva dosage adjustment
  necessary, unless patient has renal impairment (See Section 4.2).</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>When concomitant administration with co-trimoxazole is warranted,
  patients should be monitored clinically. High doses of </span><span
  lang=EN-GB>trimethoprim/ sulfamethoxazole<span style='color:black'> for the
  treatment of <i>Pneumocystis </i></span><i>jirovecii</i><i> </i><span
  style='color:black'>pneumonia (PCP) and toxoplasmosis have not been studied
  and should be avoided.</span></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Trimethoprim/sulfamethoxazole
  (Co-trimoxazole)/Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Interaction not studied.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ANTIFUNGALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fluconazole/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As only
  limited data are available the clinical significance is not known. Monitor
  for signs of zidovudine toxicity (see section 4.8).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fluconazole/Zidovudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(400&nbsp;mg
  once daily/200&nbsp;mg thrice daily)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&shy;</span><span
  lang=EN-GB>74%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='background:yellow'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(UGT
  inhibition)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ANTIMYCOBACTERIALS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rifampicin/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Insufficient data to recommend dosage adjustment.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rifampicin/Zidovudine
  (600&nbsp;mg once daily/200&nbsp;mg thrice daily)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&macr;</span><span
  lang=EN-GB>48%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(UGT
  induction)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='color:black'>ANTICONVULSANTS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenobarbital/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>Insufficient data to recommend dosage adjustment.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenobarbital/Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Potential to
  slightly decrease zidovudine plasma concentrations through UGT induction.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenytoin/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Monitor
  phenytoin concentrations.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenytoin/Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenytoin AUC </span><span
  lang=EN-GB style='font-family:Symbol'>&shy;&macr;</span><span lang=EN-GB> </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Valproic
  acid/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As only
  limited data are available the clinical significance is not known. Monitor
  for signs of zidovudine toxicity (see section 4.8).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Valproic acid/Zidovudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(250&nbsp;mg
  or 500&nbsp;mg thrice daily/100&nbsp;mg thrice daily)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&shy;</span><span
  lang=EN-GB>80%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='background:aqua'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(UGT
  inhibition)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>ANTIHISTAMINES
  (HISTAMINE H1 RECEPTOR ANTAGONISTS)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ran</span><span
  lang=IT>itidine/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Clinically significant interaction
  unlikely. </span><span lang=EN-GB>Ranitidine <span style='color:black;
  layout-grid-mode:line'>eliminated only in part by renal organic cation
  transport system.</span></span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>No dosage adjustment necessary.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ranitidine/Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Interaction not studied</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Cimetidine/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Clinically significant interaction
  unlikely. </span><span lang=EN-GB>Cimetidine <span style='color:black;
  layout-grid-mode:line'>eliminated only in part by renal organic cation
  transport system.</span></span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>No dosage adjustment necessary.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cimetidine/Zidovudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>Interaction not studied.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>CYTOTOXICS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Cladribine/Lamivudine</span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif;color:black;layout-grid-mode:line'>Interaction not
  studied</span></p>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif;color:black;layout-grid-mode:line'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>In vitro</span></i><span
  lang=EN-GB style='color:black;layout-grid-mode:line'> lamivudine inhibits the
  intracellular phosphorylation of cladribine leading to a potential risk of
  cladribine loss of efficacy in case of combination in the clinical setting.
  Some clinical findings also support a possible interaction between lamivudine
  and cladribine</span></p>
  </td>
  <td width="32%" valign=top style='width:32.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tabletextNS><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif;color:black;layout-grid-mode:line'>Therefore the
  concomitant use of lamivudine with cladribine is not recommended</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;layout-grid-mode:line'>(see section 4.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>OPIOIDS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Methadone/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>As only limited data are available the
  clinical significance is not known. Monitor for signs of zidovudine toxicity
  (see section 4.8).</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Methadone dosage
  adjustment unlikely in majority of patients; occasionally methadone
  re-titration may be required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Methadone/Zidovudine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(30&nbsp;to&nbsp;90&nbsp;mg
  once daily/200&nbsp;mg every 4&nbsp;hours)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&shy;</span><span
  lang=EN-GB>43%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Methadone AUC </span><span
  lang=EN-GB style='font-family:Symbol'>&laquo;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>URICOSURIC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Probenecid/Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
  not studied.</span></p>
  </td>
  <td width="32%" rowspan=2 valign=top style='width:32.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As only
  limited data are available the clinical significance is not known. Monitor
  for signs of zidovudine toxicity (see section 4.8).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Probenecid/Zidovudine</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>(500&nbsp;mg four times daily/2&nbsp;mg/kg thrice daily)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Zidovudine AUC
  </span><span lang=EN-GB style='font-family:Symbol'>&shy;</span><span
  lang=EN-GB>106%</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>(UGT
  inhibition)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>MISCELLANEOUS</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.78%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sorbitol
  solution (3.2g&nbsp;, 10.2&nbsp;g, 13.4&nbsp;g)/ Lamivudine</span></p>
  </td>
  <td width="33%" valign=top style='width:33.58%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>Single dose
  lamivudine oral solution 300 mg </span></p>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>Lamivudine:</span></p>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span lang=EN-GB>AUC </span><span
  lang=EN-GB style='font-family:Symbol'>&macr;</span><span lang=EN-GB> 14%;
  32%; 36% </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cmax </span><span
  lang=EN-GB style='font-family:Symbol'>&macr;</span><span lang=EN-GB> 28%;
  52%, 55%.</span></p>
  </td>
  <td width="32%" valign=top style='width:32.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When possible,
  avoid chronic coadministration of <span style='color:black'>Lamivudine/Zidovudine
  Teva</span> with medicinal products containing sorbitol or other osmotic
  acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol,
  lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load
  when chronic coadministration cannot be avoided.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abbreviations: </span><span
lang=EN-GB style='font-family:Symbol'>&shy;</span><span lang=EN-GB> = Increase;
</span><span lang=EN-GB style='font-family:Symbol'>&macr;</span><span
lang=EN-GB>=decrease; </span><span lang=EN-GB style='font-family:Symbol'>&laquo;</span><span
lang=EN-GB>= no significant change; AUC=area under the concentration versus
time curve; C<sub>max</sub>=maximum observed concentration; CL/F=apparent oral
clearance</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Exacerbation of anaemia due to ribavirin
has been reported when zidovudine is part of the regimen used to treat HIV
although the exact mechanism remains to be elucidated. The concomitant use of
ribavirin with zidovudine is not recommended due to an increased risk of
anaemia (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Consideration should be given to replacing
zidovudine in a combination ART regimen if this is already established. This
would be particularly important in patients with a known history of zidovudine
induced anaemia.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Concomitant treatment, especially acute
therapy, with potentially <span style='color:black'>nephrotoxic or </span>myelosuppressive
medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine,
co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon,
vincristine, vinblastine and doxorubicin) may also increase the risk of adverse
reactions to zidovudine. If concomitant therapy with Lamivudine/Zidovudine Teva
and any of these medicinal products is necessary then extra care should be
taken in monitoring renal function and haematological parameters and, if
required, the dosage of one or more agents should be reduced.</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited data from clinical trials do not
indicate a significantly increased risk of adverse reactions to zidovudine with
cotrimoxazole (see interaction information above relating to lamivudine and
co-trimoxazole), aerosolised pentamidine, pyrimethamine and acyclovir at doses
used in prophylaxis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.6<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u><i><span lang=EN-GB>
</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and
consequently for reducing the risk of HIV vertical transmission to the newborn,
the animal data as well as the clinical experience in pregnant women should be
taken into account. In the present case, the use in pregnant women of
zidovudine, with subsequent treatment of the newborn infants, has been shown to
reduce the rate of maternal-foetal transmission of HIV. A large amount of data
on pregnant women taking lamivudine or zidovudine indicate no malformative toxicity
(more than 3000 outcomes from first trimester exposure each of which over 2000
outcomes involved exposure to both lamivudine and zidovudine). The malformative
risk is unlikely in humans based on the mentioned large amount of data.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The active ingredients of
Lamivudine/Zidovudine Teva may inhibit cellular DNA replication and zidovudine has
been shown to be transplacental carcinogen in one animal study (see section
5.3). The clinical relevance of these findings is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For patients co-infected with hepatitis who
are being treated with lamivudine containing medicinal products such as
Lamivudine/Zidovudine Teva and subsequently become pregnant, consideration
should be given to the possibility of a recurrence of hepatitis on
discontinuation of lamivudine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Mitochondrial dysfunction: nucleoside and
nucleotide analogues have been demonstrated in vitro and in vivo to cause a
variable degree of mitochondrial damage. There have been reports of
mitochondrial dysfunction in HIV-negative infants exposed in utero and/or
post-natally to nucleoside analogues (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breastfeeding</span></u><span
lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Both lamivudine and zidovudine are excreted
in breast milk at similar concentrations to those found in serum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Based on more than 200<span
style='border:none windowtext 1.0pt;padding:0in'> </span>mother/child pairs
treated for HIV, serum concentrations of lamivudine in breastfed infants of
mothers treated for HIV are very low (&lt; 4% of maternal serum concentrations)
and progressively decrease to undetectable levels when breastfed infants reach
24 weeks of age. There are no data available on the safety of lamivudine when
administered to babies less than three months old.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After administration of a single dose of
200&nbsp;mg zidovudine to HIV-infected women, the mean concentration of
zidovudine was similar in human milk and serum.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It is recommended that mothers infected by
HIV do not breast-feed their infants under any circumstances in order to avoid
transmission of HIV.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Fertility</span></u><span lang=EN-GB> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Neither zidovudine nor lamivudine have
shown evidence of impairment of fertility in studies in male and female rats.
There are no data on their affect on human female fertility. </span></p>

<p class=MsoNormal><span lang=EN-GB>In men zidovudine has not been shown to
affect sperm count, morphology or motility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No studies on the effects on the ability to
drive and use machines have been performed. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions have been reported during
therapy for HIV disease with lamivudine and zidovudine separately or in
combination. For many of these events, it is unclear whether they are related
to lamivudine, zidovudine, the wide range of medicinal products used in the
management of HIV disease, or as a result of the underlying disease process. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As Lamivudine/Zidovudine Teva contains
lamivudine and zidovudine, the type and severity of adverse reactions
associated with each of the compounds may be expected. There is no evidence of
added toxicity following concurrent administration of the two compounds. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of lactic acidosis, sometimes fatal,
usually associated with severe hepatomegaly and hepatic steatosis, have been
reported with the use of zidovudine (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
layout-grid-mode:line'>Treatment with zidovudine has been associated with loss
of subcutaneous fat which is most evident in the face, limbs and buttocks.
Patients receiving </span><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span style='color:black;layout-grid-mode:line'> should be
frequently examined and questioned for signs of lipoatrophy. When such
development is found, treatment with </span><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span lang=EN-GB style='color:black;layout-grid-mode:line'> </span><span
style='color:black;layout-grid-mode:line'>should not be continued (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
layout-grid-mode:line'>Weight and levels of blood lipids and glucose may
increase during antiretroviral therapy (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In HIV-infected patients with severe immune
deficiency at the time of initiation of combination antiretroviral therapy
(CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. Autoimmune disorders (such as Graves&#8217; disease and
autoimmune hepatitis) have also been reported to occur in the setting of immune
reactivation; however, the reported time to onset is more variable and these
events can occur many months after initiation of treatment (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long-term exposure to combination antiretroviral therapy (CART). The
frequency of this is unknown (see section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:12.9pt;line-height:12.8pt;text-autospace:
none'><b><span lang=EN-GB>Lamivudine: </span></b></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reactions considered at least
possibly related to the treatment are listed below by body system, organ class
and absolute frequency. Frequencies are defined as very common (&#8805;1/10),
common (&#8805;1/100 to &lt;1/10), uncommon (&#8805;1/1000 to &lt;1/100), rare
(&#8805;1/10,000 to &lt;1/1000), very rare (&lt;1/10,000). Within each frequency
grouping, undesirable effects are presented in order of decreasing seriousness.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood and lymphatic systems disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon:</span></i><span lang=EN-GB>
Neutropenia and anaemia (both occasionally severe), thrombocytopenia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Very rare:</span></i><span lang=EN-GB>
Pure red cell aplasia </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Metabolism and nutrition disorders</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>Very Rare: </span></i><span lang=EN-GB style='color:black'>Lactic
acidosis</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Nervous system disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common: </span></i><span lang=EN-GB>Headache,
insomnia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Very rare:</span></i><span lang=EN-GB>
Peripheral neuropathy (or paraesthesiae) </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Respiratory, thoracic and mediastinal
disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common:</span></i><span lang=EN-GB>
Cough, nasal symptoms </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Gastrointestinal disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common: </span></i><span lang=EN-GB>Nausea,
vomiting, abdominal pain or cramps, diarrhoea </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>
Pancreatitis, rises in serum amylase </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Hepatobiliary disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon:</span></i><span lang=EN-GB>
Transient rises in liver enzymes (AST, ALT) </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>
Hepatitis </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Skin and subcutaneous tissue disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common:</span></i><span lang=EN-GB>
Rash, alopecia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare: </span></i><span lang=EN-GB>Angioedema</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Musculoskeletal and connective tissue
disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common: </span></i><span lang=EN-GB>Arthralgia,
muscle disorders</span></p>

<p class=MsoNormal style='margin-right:237.85pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB> Rhabdomyolysis </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>General disorders and administration
site conditions </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common:</span></i><span lang=EN-GB>
Fatigue, malaise, fever </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:12.9pt;line-height:12.8pt;text-autospace:
none'><b><span lang=EN-GB>Zidovudine: </span></b></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reactions profile appears
similar for adults and adolescents. The most serious adverse reactions include
anaemia (which may require transfusions), neutropenia and leucopenia. These
occurred more frequently at higher dosages (1200&#8209;1500&nbsp;mg/day) and in
patients with advanced HIV disease (especially when there is poor bone marrow
reserve prior to treatment), and particularly in patients with CD4 cell counts
less than 100/mm<sup><span style='position:relative;top:-5.0pt'>3</span></sup>&nbsp;(see
section 4.4). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of neutropenia was also
increased in those patients whose neutrophil counts, haemoglobin levels and
serum vitamin B</span><span lang=EN-GB style='font-size:7.0pt'>12</span><span
lang=EN-GB> levels were low at the start of zidovudine therapy. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reactions considered at least
possibly related to the treatment are listed below by body system, organ class
and absolute frequency. Frequencies are defined as very common (&#8805;1/10),
common (&#8805;1/100 to &lt;1/10), uncommon (&#8805;1/1000 to &lt;1/100), rare
(&#8805;1/10,000 to &lt;1/1000), very rare (&lt;1/10,000). Within each
frequency grouping, undesirable effects are presented in order of decreasing
seriousness.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Blood and lymphatic system disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common:</span></i><span lang=EN-GB>
Anaemia, neutropenia and leucopenia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon:</span></i><span lang=EN-GB>
Thrombocytopenia and pancytopenia (with marrow hypoplasia) </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB> Pure
red cell aplasia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Very rare:</span></i><span lang=EN-GB>
Aplastic anaemia </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Metabolism and nutrition disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare: </span></i><span lang=EN-GB>Lactic
acidosis in the absence of hypoxaemia, anorexia </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Psychiatric disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>
Anxiety and depression </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Nervous system disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Very common</span></i><span lang=EN-GB>:
Headache </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Common:</span></i><span lang=EN-GB>
Dizziness </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>
Insomnia, paraesthesiae, somnolence, loss of mental acuity, convulsions </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Cardiac disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>Cardiomyopathy
</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Respiratory, thoracic and mediastinal
disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon</span></i><span lang=EN-GB>:
Dyspnoea </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB> Cough </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Gastrointestinal disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Very common</span></i><span lang=EN-GB>:
Nausea </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Common</span></i><span lang=EN-GB>:
Vomiting, abdominal pain and diarrhoea </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon:</span></i><span lang=EN-GB>
Flatulence </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB> Oral
mucosa pigmentation, taste perversion and dyspepsia. Pancreatitis </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Hepatobiliary disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common</span></i><span lang=EN-GB>:
Raised blood levels of liver enzymes and bilirubin </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare :</span></i><span lang=EN-GB> Liver
disorders such as severe hepatomegaly with steatosis </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Skin and subcutaneous tissue disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon:</span></i><span lang=EN-GB>
Rash and pruritus </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB> Nail
and skin pigmentation, urticaria and sweating</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Musculoskeletal and connective tissue
disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common</span></i><span lang=EN-GB>:
Myalgia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon</span></i><span lang=EN-GB>:
Myopathy </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Renal and urinary disorders </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>
Urinary frequency </span></p>

<p class=MsoNormal style='margin-right:320.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Reproductive system and breast disorders
</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare:</span></i><span lang=EN-GB>
Gynaecomastia </span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>General disorders and administration
site conditions </span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>Common</span></i><span lang=EN-GB>:
Malaise</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Uncommon</span></i><span lang=EN-GB>:
Fever, generalised pain and asthenia </span></p>

<p class=MsoNormal><i><span lang=EN-GB>Rare: </span></i><span lang=EN-GB>Chills,
chest pain and influenza-like syndrome </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The available data from both
placebo-controlled and open-label studies indicate that the incidence of nausea
and other frequently reported clinical adverse events consistently decreases
over time during the first few weeks of therapy with zidovudine. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience of overdosage
with lamivudine/zidovudine. No specific symptoms or signs have been identified following
acute overdose with zidovudine or lamivudine apart from those listed as
undesirable effects. No fatalities occurred, and all patients recovered. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If overdosage occurs the patient should be
monitored for evidence of toxicity (see section 4.8), and standard supportive
treatment applied as necessary. Since lamivudine is dialysable, continuous
haemodialysis could be used in the treatment of overdosage, although this has
not been studied. Haemodialysis and peritoneal dialysis appear to have a limited
effect on elimination of zidovudine, but enhance the elimination of the
glucuronide metabolite. For more details physicians should refer to the
individual prescribing information for lamivudine and zidovudine. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Antivirals for
treatment of HIV infections, combinations, ATC Code: J05AR01 </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine and zidovudine are nucleoside
analogues which have activity against HIV. Additionally, lamivudine has
activity against hepatitis B virus (HBV). Both medicinal products are
metabolised intracellularly to their active moieties, lamivudine
5&#8217;-triphosphate (TP) and zidovudine 5&#8217;-TP respectively. Their main
modes of action are as chain terminators of viral reverse transcription. Lamivudine-TP
and zidovudine-TP have selective inhibitory activity against HIV-1 and HIV-2
replication <i>in vitro</i>; lamivudine is also active against
zidovudine-resistant clinical isolates of HIV. </span><span lang=EN-GB>No
antagonistic effects <i>in vitro</i> were seen with lamivudine and other
antiretrovirals (tested agents: abacavir, didanosine and nevirapine). No
antagonistic effects <i>in vitro </i>were seen with zidovudine and other
antiretrovirals (tested agents: abacavir, didanosine and interferon-alpha).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>HIV-1 resistance to lamivudine involves the
development of a M184V amino acid change close to the active site of the viral
reverse transcriptase (RT). This variant arises both <i>in vitro</i> and in
HIV-1 infected patients treated with lamivudine-containing antiretroviral
therapy. M184V mutants display greatly reduced susceptibility to lamivudine and
show diminished viral replicative capacity <i>in vitro</i>. <i><span
style='color:black'>In vitro</span></i><span style='color:black'> studies
indicate that zidovudine-resistant virus isolates can become zidovudine
sensitive when they simultaneously acquire resistance to lamivudine. The
clinical relevance of such findings remains, however, not well defined.</span></span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
data tend to suggest that the continuation of lamivudine in anti-retroviral
regimen despite the development of M184V might provide residual anti-retroviral
activity (likely through impaired viral fitness). The clinical relevance of these
findings is not established. Indeed, the available clinical data are very
limited and preclude any reliable conclusion in the field.</span></p>

<p class=MsoNormal><span lang=EN-GB>Cross-resistance conferred by the M184V RT
is limited within the nucleoside inhibitor class of antiretroviral agents.
Zidovudine and stavudine maintain their antiretroviral activities against
lamivudine-resistant HIV-1. The M184V RT mutant shows a &lt;4-fold decrease in
susceptibility to didanosine; the clinical significance of these findings is
unknown. <i>In vitro</i> susceptibility testing has not been standardised and results
may vary according to methodological factors. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine demonstrates low cytotoxicity to
peripheral blood lymphocytes, to established lymphocyte and monocyte-macrophage
cell lines, and to a variety of bone marrow progenitor cells <i>in vitro</i>.
Resistance to thymidine analogues (of which zidovudine is one) is well
characterised and is conferred by the stepwise accumulation of up to six
specific mutations in the HIV reverse transcriptase at codons 41, 67, 70, 210,
215 and 219. Viruses acquire phenotypic resistance to thymidine analogues
through the combination of mutations at codons 41 and 215 or by the
accumulation of at least four of the six mutations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Two patterns of multi-drug resistance
mutations, the first characterised by mutations in the HIV reverse
transcriptase at codons 62, 75, 77, 116 and 151 and the second involving a T69S
mutation plus a 6-base pair insert at the same position, result in phenotypic
resistance to AZT as well as to the other approved NRTIs. Either of these two
patterns of multinucleoside resistance mutations severely limits future
therapeutic options. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Clinical Experience </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In clinical trials, lamivudine in
combination with zidovudine has been shown to reduce HIV-1 viral load and
increase CD4 cell count. Clinical end-point data indicate that lamivudine in
combination with zidovudine, results in a significant reduction in the risk of
disease progression and mortality. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Evidence from clinical studies shows that <span
style='color:black'>lamivudine plus zidovudine delays the emergence of
zidovudine resistant isolates in individuals with no prior antiretroviral
therapy. </span>Subjects receiving lamivudine and zidovudine with or without
additional concomitant antiretroviral therapies and who already present with
the M184V mutant virus also experience a delay in the onset of mutations that
confer resistance to zidovudine and stavudine (Thymidine Analogue Mutations;
TAMs). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The relationship between <i>in vitro</i>
susceptibility of HIV to lamivudine and zidovudine and clinical response to
lamivudine/zidovudine containing therapy remains under investigation. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lamivudine at a dose of
100&nbsp;mg once daily has also been shown to be effective for the treatment of
adult patients with chronic HBV infection (for details of clinical studies, see
the prescribing information for lamivudine 100&nbsp;mg).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine has not been specifically
investigated in HIV patients co-infected with HBV. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Absorption</span></u><i><span
lang=EN-GB> </span></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine and zidovudine are well absorbed
from the gastrointestinal tract. The bioavailability of oral lamivudine in
adults is normally between 80&#8209;85&nbsp;% and for zidovudine 60&#8209;70&nbsp;%.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A bioequivalence study compared lamivudine/zidovudine
with lamivudine 150&nbsp;mg and zidovudine 300&nbsp;mg tablets taken together.
The effect of food on the rate and extent of absorption was also studied. Lamivudine/zidovudine
was shown to be bioequivalent to lamivudine 150&nbsp;mg and zidovudine
300&nbsp;mg given as separate tablets, when administered to fasting subjects. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Following single dose lamivudine/zidovudine
administration in healthy volunteers, mean (CV) lamivudine and zidovudine C</span><span
lang=EN-GB style='font-size:7.0pt'>max</span><span lang=EN-GB> values were
1.6&nbsp;&micro;g/ml (32&nbsp;%) and 2.0&nbsp;&micro;g/ml (40&nbsp;%),
respectively and the corresponding values for AUC were 6.1&nbsp;&micro;g h/ml
(20&nbsp;%) and 2.4&nbsp;&micro;g h/ml (29&nbsp;%) respectively. The median
(range) lamivudine and zidovudine t</span><span lang=EN-GB style='font-size:
7.0pt'>max </span><span lang=EN-GB>values were 0.75 (0.50&#8209;2.00) hours and
0.50 (0.25&#8209;2.00) hours respectively. The extent of lamivudine and
zidovudine absorption (AUC</span><span lang=EN-GB style='font-size:7.0pt'>&#8734;</span><span
lang=EN-GB>) and estimates of half-life following administration of lamivudine/zidovudine
with food were similar when compared to fasting subjects, although the rates of
absorption (C</span><span lang=EN-GB style='font-size:7.0pt'>max, </span><span
lang=EN-GB>t</span><span lang=EN-GB style='font-size:7.0pt'>max</span><span
lang=EN-GB>) were slowed. Based on these data lamivudine/zidovudine may be
administered with or without food. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of crushed tablets with a
small amount of semi-solid food or liquid would not be expected to have an
impact on the pharmaceutical quality, and would therefore not be expected to
alter the clinical effect. This conclusion is based on the physicochemical and
pharmacokinetic data assuming that the patient crushes and transfers 100&nbsp;%
of the tablet and ingests immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous studies with lamivudine and
zidovudine showed that the mean apparent volume of distribution is 1.3 and
1.6&nbsp;l/kg respectively. Lamivudine exhibits linear pharmacokinetics over
the therapeutic dose range and displays limited binding to the major plasma
protein albumin (&lt;36&nbsp;% serum albumin <i>in vitro</i>). Zidovudine
plasma protein binding is 34&nbsp;% to 38&nbsp;%. Interactions involving binding
site displacement are not anticipated with Lamivudine/Zidovudine Teva. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Data show that lamivudine and zidovudine
penetrate the central nervous system (CNS) and reach the cerebrospinal fluid
(CSF). The mean ratios of CSF/serum lamivudine and zidovudine concentrations
2-4 hours after oral administration were approximately 0.12 and 0.5
respectively. The true extent of CNS penetration of lamivudine and its
relationship with any clinical efficacy is unknown. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Biotransformation</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Metabolism of lamivudine is a minor route
of elimination. Lamivudine is predominately cleared unchanged by renal
excretion. The likelihood of metabolic drug interactions with lamivudine is low
due to the small extent of hepatic metabolism (5&#8209;10&nbsp;%) and low
plasma binding. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The 5&#8217;-glucuronide of zidovudine is
the major metabolite in both plasma and urine, accounting for approximately 50&#8209;80&nbsp;%
of the administered dose eliminated by renal excretion. 3&#8217;-amino-3&#8217;&shy;deoxythymidine
(AMT) has been identified as a metabolite of zidovudine following intravenous
dosing. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u><i><span
lang=EN-GB> </span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The observed lamivudine half-life of elimination
is 5 to 7 hours. The mean systemic clearance of lamivudine is approximately
0.32&nbsp;l/h/kg, with predominantly renal clearance (&gt;70&nbsp;%) via the
organic cationic transport system. Studies in patients with renal impairment
show lamivudine elimination is affected by renal dysfunction. Dose reduction is
required for patients with creatinine clearance &#8804;50&nbsp;ml/min (see
section 4.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>From studies with intravenous zidovudine,
the mean terminal plasma half-life was 1.1 hours and the mean systemic
clearance was 1.6&nbsp;l/h/kg. Renal clearance of zidovudine is estimated to be
</span><span lang=EN-GB>0.34&nbsp;l/h/kg, indicating glomerular filtration and
active tubular secretion by the kidneys. Zidovudine concentrations are
increased in patients with advanced renal failure. </span></p>

<p class=MsoNormal style='margin-right:4.55pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>Pharmacokinetics in children:</span></i><span
lang=EN-GB> In children over the age of 5-6 months, the pharmacokinetic profile
of zidovudine is similar to that in adults. Zidovudine is well absorbed from
the gut and at all dose levels studied in adults and children, the
bioavailability was between 60&#8209;74&nbsp;% with a mean of 65&nbsp;%. Css</span><span
lang=EN-GB style='font-size:7.0pt'>max </span><span lang=EN-GB>levels were 4.45
&#956;M (1.19&nbsp;&#956;g/ml) following a dose of 120&nbsp;mg zidovudine (in
solution)/m<sup>2</sup> body surface area and 7.7&nbsp;&#956;M
(2.06&nbsp;&#956;g/ml) at 180&nbsp;mg/m<sup>2</sup> body surface area. Dosages
of 180&nbsp;mg/m<sup>2</sup> four times daily in children produced similar
systemic exposure (24 hour AUC 40.0&nbsp;h&nbsp;&#956;M or
10.7&nbsp;h&nbsp;&#956;g/ml) as doses of 200&nbsp;mg six times daily in adults
(40.7&nbsp;h&nbsp;&#956;M or 10.9&nbsp;h&nbsp;&#956;g/ml). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In six HIV-infected children from 2 to 13
years of age, zidovudine plasma pharmacokinetics were evaluated while subjects
were receiving 120&nbsp;mg/m<sup>2</sup> zidovudine three times daily and again
after switching to 180&nbsp;mg/m<sup>2</sup> twice daily. Systemic exposures
(daily AUC and C</span><span lang=EN-GB style='font-size:7.0pt'>max</span><span
lang=EN-GB>) in plasma from the twice daily regimen appeared equivalent to
those from the same total daily dose given in three divided doses [Bergshoeff,
2004]. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In general, lamivudine pharmacokinetics in
paediatric patients are similar to adults. However, absolute bioavailability
(approximately 55&#8209;65&nbsp;%) was reduced in paediatric patients below 12
years of age. In addition, systemic clearance values were greater in younger
paediatric patients and decreased with age, approaching adult values around 12
years of age. Due to these differences, the recommended dose for lamivudine in
children (aged more than three months and weighing less than 30&nbsp;kg) is
4&nbsp;mg/kg twice a day. This dose will achieve an average AUC</span><span
lang=EN-GB style='font-size:7.0pt'>0-12</span><span lang=EN-GB> ranging from
approximately 3,800 to 5,300&nbsp;ng&nbsp;h/ml. Recent findings indicate that
exposure in children &lt;6 years of age may be reduced by about 30&nbsp;% compared
with other age groups. Further data addressing this issue are currently
awaited. At present, the available data do not suggest that lamivudine is less
efficacious in this age group. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Pharmacokinetics in pregnancy: </span></i><span
lang=EN-GB>The pharmacokinetics of lamivudine and zidovudine were similar to
that of non-pregnant women. </span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The clinically relevant effects of
lamivudine and zidovudine in combination are anaemia, neutropenia and
leucopenia. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Mutagenicity and carcinogenicity</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Neither lamivudine nor zidovudine are
mutagenic in bacterial tests, but consistent with other nucleoside analogues,
inhibit cellular DNA replication in <i>in vitro</i> mammalian tests such as the
mouse lymphoma assay. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine has not shown any genotoxic activity
in <i>in vivo</i> studies at doses that gave plasma concentrations up to 40&#8209;50
times higher than clinical plasma levels. Zidovudine showed clastogenic effects
in an oral repeated dose micronucleus test in mice. Peripheral blood
lymphocytes from AIDS patients receiving zidovudine treatment have also been
observed to contain higher numbers of chromosome breakages. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A pilot study has demonstrated that
zidovudine is incorporated into leukocyte nuclear DNA of adults, including
pregnant women, taking zidovudine as treatment for HIV-1 infection, or for the
prevention of mother to child viral transmission. Zidovudine was also
incorporated into DNA from cord blood leukocytes of infants from
zidovudine-treated mothers. A transplacental genotoxicity study conducted in monkeys
compared zidovudine alone with the combination of zidovudine and lamivudine at
human-equivalent exposures. The study demonstrated that foetuses exposed <i>in
utero</i> to the combination sustained a higher level of nucleoside
analogue-DNA incorporation into multiple foetal organs, and showed evidence of
more telomere shortening than in those exposed to zidovudine alone. The
clinical significance of these findings is unknown. </span></p>

<p class=MsoNormal style='line-height:12.8pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.8pt;text-autospace:none'><span
lang=EN-GB>The carcinogenic potential of a combination of lamivudine and
zidovudine has not been tested. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In long-term oral carcinogenicity studies
in rats and mice, lamivudine did not show any carcinogenic potential. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In oral carcinogenicity studies with
zidovudine in mice and rats, late appearing vaginal epithelial tumours were
observed. A subsequent intravaginal carcinogenicity study confirmed the
hypothesis that the vaginal tumours were the result of long term local exposure
of the rodent vaginal epithelium to high concentrations of unmetabolised
zidovudine in urine. There were no other zidovudine-related tumours observed in
either sex of either species. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In addition, two transplacental
carcinogenicity studies have been conducted in mice. In one study, by the US
National Cancer Institute, zidovudine was administered at maximum tolerated
doses to pregnant mice from day 12 to 18 of gestation. One year post-natally,
there was an increase in the incidence of tumours in the lung, liver and female
reproductive tract of offspring exposed to the highest dose level
(420&nbsp;mg/kg term body weight). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a second study, mice were administered
zidovudine at doses up to 40&nbsp;mg/kg for 24 months, with exposure beginning
prenatally on gestation day 10. Treatment related findings were limited to
late-occurring vaginal epithelial tumours, which were seen with a similar
incidence and time of onset as in the standard oral carcinogenicity study. The
second study thus provided no evidence that zidovudine acts as a transplacental
carcinogen. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>While the clinical relevance of these
findings is unknown, these data suggest that a carcinogenic risk to humans is
outweighed by the potential clinical benefit. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In reproductive toxicity studies lamivudine
has demonstrated evidence of causing an increase in early embryonic deaths in
the rabbit at relatively low systemic exposures, comparable to those achieved
in man, but not in the rat even at very high systemic exposure. Zidovudine had
a similar effect in both species, but only at very high systemic exposures. Lamivudine
was not teratogenic in animal studies. At maternally toxic doses, zidovudine
given to rats during organogenesis resulted in an increased incidence of
malformations, but no evidence of foetal abnormalities was observed at lower
doses.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Tablet core</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cellulose,
microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium starch
glycolate (Type A)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium stearyl
fumarate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Tablet
film-coat</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypromellose 3cP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypromellose 6cP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Polysorbate 80</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Macrogol 400</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Titanium dioxide
E171</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30 months</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Blisters:</span></p>

<p class=MsoNormal><span lang=EN-GB>OPA/Alu/PVC Aluminium blisters</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Containers:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White opaque
HDPE containers with white opaque polyethylene child resistant screw cap with
Aluminium seal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each pack type contains 60 film-coated
tablets.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
disposal</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>No special requirements for disposal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 02 March 2011</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 19 November 2015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this medicinal product
is available on the website of the European Medicines Agency </span><span
lang=EN-GB><a href="http://www.emea.europa.eu">http://www.ema.europa.eu</a></span><span
lang=EN-GB style='color:blue'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS </span></b><b><span
lang=EN-GB>OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-7.05pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>C.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=ListParagraph1><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>D.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>CONDITIONS OR RESTRICTIONS WITH REGARDS
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-42.5pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB
style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:9.0pt;font-family:"Verdana",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva
Pharmaceutical Works Private Limited Company</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pallagi
&uacute;t 13</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Debrecen</span><span
lang=EN-GB> H-4042</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Pharmachemie B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2031 GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=PL>Teva Operations
Poland Sp. z.o.o.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>80 Mogilska St</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>31-546 Krakow</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Poland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=DE>Merckle GmbH</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=DE>Ludwig-Merckle-Strasse
3</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=DE>89143 Blaubeuren</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:7.0pt;line-height:14.0pt'><span
lang=EN-GB>The printed package leaflet of the medicinal product must state the
name and address of the manufacturer responsible for the release of the
concerned batch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS </span><span
lang=EN-GB>OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (See Annex I: Summary of
Product Characteristics, Section 4.2)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The marketing authorisation holder shall
submit periodic safety update reports for this product in accordance with the
requirements set out in the list of Union reference dates (EURD list) provided
for under article 107c(7) of Directive 2001/83/EC and published on the European
medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON &#8211; BLISTER PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Lamivudine/Zidovudine Teva 150&nbsp;mg/300&nbsp;mg
film-coated tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine/zidovudine </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine 150&nbsp;mg </span></p>

<p class=MsoNormal><span lang=EN-GB>zidovudine 300&nbsp;mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60 film-coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/002</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
 style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine/Zidovudine
Teva</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>2D
barcode carrying the unique identifier included.</span><span lang=EN-GB
style='color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:39.25pt'>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:39.25pt'>
  <p class=MsoNormal><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON
  BLISTERS OR STRIPS</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=EN-GB>BLISTER FOIL</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lamivudine/Zidovudine Teva
150&nbsp;mg/300&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine/zidovudine </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MARKETING AUTHORISATION HOLDER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><i><span
lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal'><b><span lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON FOR THE CONTAINER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Lamivudine/Zidovudine Teva 150&nbsp;mg/300&nbsp;mg
film-coated tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine/zidovudine </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine 150&nbsp;mg </span></p>

<p class=MsoNormal><span lang=EN-GB>zidovudine 300&nbsp;mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60 film-coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/002</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
 style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lamivudine/Zidovudine
Teva</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>2D
barcode carrying the unique identifier included.</span><span lang=EN-GB
style='color:green'> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CONTAINERS</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Lamivudine/Zidovudine Teva 150&nbsp;mg/300&nbsp;mg
film-coated tablets </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine/zidovudine </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each film-coated tablet contains </span></p>

<p class=MsoNormal><span lang=EN-GB>lamivudine 150&nbsp;mg </span></p>

<p class=MsoNormal><span lang=EN-GB>zidovudine 300&nbsp;mg </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>60 film-coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/10/663/002</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='color:black'>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Lamivudine/Zidovudine Teva 150&nbsp;mg/300&nbsp;mg film-coated
tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
lang=EN-GB>lamivudine/zidovudine</span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine</span></b><b><span
lang=EN-GB style='color:black'> because it contains important information for
you</span><span lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their </span><span lang=EN-GB
style='color:black'>signs of illness</span><span lang=EN-GB> are the same as
yours.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any of the side effects </span><span lang=EN-GB
style='color:black'>talk to your doctor or pharmacist. This includes any
possible</span><span lang=EN-GB> side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Lamivudine/Zidovudine
Teva is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before
you take Lamivudine/Zidovudine Teva</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
Lamivudine/Zidovudine Teva</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:
normal'><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to store Lamivudine/Zidovudine Teva</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=EN-GB
style='color:black'>Contents of the pack and other</span><span lang=EN-GB>
information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Lamivudine/Zidovudine Teva is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Lamivudine/Zidovudine Teva </span></b><b><span lang=EN-GB
style='color:black'>is used to treat HIV (human immunodeficiency virus)
infection in adults and children.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lamivudine/Zidovudine Teva contains two active ingredients
that are used to treat HIV infection: lamivudine and zidovudine. Both of these
belong</span><span lang=EN-GB style='color:black'> to a group of </span><span
lang=EN-GB style='color:black'>anti-retroviral</span><span lang=EN-GB
style='color:black'> medicines called <i>nucleoside analogue reverse
transcriptase inhibitors</i> (<i>NRTIs</i>)<i>.</i></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lamivudine/Zidovudine Teva </span><span lang=EN-GB
style='color:black'>does not completely cure HIV infection; it </span><span
lang=EN-GB style='color:black'>reduces the amount of virus in your body, and
keeps it at a low level. It also increases </span><span lang=EN-GB
style='color:black'>the </span><span lang=EN-GB style='color:black'>CD4 cell </span><span
lang=EN-GB style='color:black'>count in your blood</span><span lang=EN-GB
style='color:black'>. CD4 cells are a type of white blood </span><span
lang=EN-GB style='color:black'>cells</span><span lang=EN-GB style='color:black'>
that </span><span lang=EN-GB style='color:black'>are</span><span lang=EN-GB
style='color:black'> important in </span><span lang=EN-GB style='color:black'>helping
your body to </span><span lang=EN-GB style='color:black'>fight infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Not everyone responds</span><span lang=EN-GB
style='color:black'> to treatment with Lamivudine/Zidovudine Teva </span><span
lang=EN-GB style='color:black'>in the same way. </span><span lang=EN-GB
style='color:black'>Your doctor will </span><span lang=EN-GB style='color:black'>monitor</span><span
lang=EN-GB style='color:black'> the effectiveness of your treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you take
Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are
allergic to lamivudine or zidovudine or any of the other ingredients of this
medicine (</span><i><span lang=EN-GB style='color:black'>listed in section 6</span></i><span
lang=EN-GB>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you
have <b>a </b></span><b><span lang=EN-GB>very low red blood cell count</span></b><span
lang=EN-GB> (</span><i><span lang=EN-GB>anaemia</span></i><span lang=EN-GB>) or
<b>a </b></span><b><span lang=EN-GB>very low white blood cell count</span></b><span
lang=EN-GB> (</span><i><span lang=EN-GB>neutropenia</span></i><span lang=EN-GB>).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:28.35pt;line-height:normal'><b><span lang=EN-GB style='color:black'>Check
with</span><span lang=EN-GB style='color:black'> your doctor</span></b><span
lang=EN-GB style='color:black'> if you think any of these apply to you</span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Take special care with Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>Some people taking </span><span lang=EN-GB
style='color:black'>Lamivudine/Zidovudine Teva </span><span lang=EN-GB
style='color:black'>or other combination treatments for HIV are more at risk of
serious side effects. You need to be aware of the extra risks:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you have ever had<b>
liver disease, </b>including hepatitis B or C (if you have hepatitis B infection,
do not stop Lamivudine/Zidovudine Teva without</span><span lang=EN-GB
style='color:black'> your </span><span lang=EN-GB style='color:black'>doctor&#8217;s
advice, as your hepatitis may come back)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you have <b>kidney
disease</b></span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are seriously<b> overweight</b>
(especially if you&#8217;re a woman).</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
margin-left:28.35pt;line-height:normal'><b><span lang=EN-GB style='color:black'>Talk</span><span
lang=EN-GB style='color:black'> to </span></b><b><span lang=EN-GB
style='color:black'>your doctor if any</span><span lang=EN-GB style='color:
black'> of </span></b><b><span lang=EN-GB style='color:black'>these apply to
you. </span></b><span lang=EN-GB style='color:black'>Your doctor will decide if
</span><span lang=EN-GB style='color:black'>the active substances are suitable
for you. </span><span lang=EN-GB style='color:black'>You may need extra
check-ups, including blood tests, while you are taking your medicine. See
Section 4 for more information.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Look out for</span><span lang=EN-GB style='color:black'>
important symptoms</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>Some people taking </span><span lang=EN-GB
style='color:black'>medicines </span><span lang=EN-GB style='color:black'>for
HIV infection develop other conditions, which can be serious. You need to know
about important signs and symptoms to look out for while you are taking </span><span
lang=EN-GB style='color:black'>Lamivudine/Zidovudine Teva.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:.25in;text-indent:10.35pt;line-height:normal'><b><span lang=EN-GB
style='color:black'>Read the information &#8216;Other possible side effects of
combination therapy for HIV&#8217; in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section
4 of this leaflet.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Protect other people </span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>HIV infection is spread by sexual contact with
someone who has the infection, or by transfer of infected blood (for example,
by sharing injection needles). You can still pass on HIV when taking this
medicine, although the risk is lowered by effective antiretroviral therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Discuss with your doctor the precautions needed to avoid
infecting other people.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Other medicines and Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Tell your doctor or pharmacist if you&#8217;re taking any
other medicines, </span></b><span lang=EN-GB style='color:black'>or if you have
taken any recently, including herbal medicines or other medicines you bought
without a prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>Remember to tell your doctor or pharmacist if
you begin taking a new medicine while you are taking Lamivudine/Zidovudine
Teva.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>These medicines should not be used with
Lamivudine/Zidovudine Teva:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>other medicinal products
containing lamivudine, to treat <b>HIV infection or hepatitis B infection</b></span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>emtricitabine, to treat<b>
HIV infection</b></span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>stavudine or zalcitabine,<b>
</b>to treat<b> HIV infection</b></span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>ribavirin or injections of
ganciclovir to treat <b>viral infections</b></span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>high doses of <b>co-trimoxazole</b>,<b>
</b>an antibiotic.</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cladribine, used to treat <b>hairy cell
leukaemia</b></span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Tell your doctor </span></b><span lang=EN-GB
style='color:black'>if you are being treated with any of these.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Some medicines can make it more likely that you&#8217;ll
have side effects, or make side effects worse. </span></b><span lang=EN-GB
style='color:black'>These include:</span></p>

<p class=MsoNormal style='margin-left:1.55in;text-indent:-1.55in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>sodium valproate,<b> </b>to
treat <b>epilepsy</b></span></p>

<p class=MsoNormal style='margin-left:1.55in;text-indent:-1.55in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>interferon,<b> </b>to treat <b>viral
infections</b></span></p>

<p class=MsoNormal style='margin-left:1.55in;text-indent:-1.55in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>pyrimethamine, to treat <b>malaria</b>
and other parasitic infections</span></p>

<p class=MsoNormal style='margin-left:1.55in;text-indent:-1.55in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>dapsone,<b> </b>to prevent <b>pneumonia</b>
and treat skin infections</span></p>

<p class=MsoNormal style='margin-left:1.55in;text-indent:-1.55in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>fluconazole or flucytosine<b>,
</b>to treat <b>fungal infections </b>such as <b>candida</b></span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>pentamidine or atovaquone<b>
</b>to treat parasitic infections such as Pneumocystis jirovecii pneumonia
(often referred to as <b>PCP</b>)</span></p>

<p class=MsoNormal style='margin-left:1.55in;text-indent:-1.55in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>amphotericin or
co-trimoxazole,<b> </b>to treat <b>fungal and bacterial infections</b></span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>probenecid,<b> </b>to treat <b>gout</b>
and similar conditions, and given with some antibiotics to make them more
effective</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>methadone, </span></b><span
lang=EN-GB style='color:black'>used as a <b>heroin substitute</b></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:21.25pt;text-indent:-21.25pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>vincristine, vinblastine or
doxorubicin<b>, </b>to treat <b>cancer.</b></span></p>

<p class=MsoNormal style='margin-left:21.3pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Tell your doctor </span></b><span lang=EN-GB
style='color:black'>if you are taking any of these.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Some medicines interact with Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>These include:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:21.55pt;text-indent:-21.55pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>clarithromycin,</span></b><span
lang=EN-GB style='color:black'> an antibiotic</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:21.3pt;line-height:normal'><span lang=EN-GB style='color:black'>if
you are taking clarithromycin, take your dose at least 2 hours before or after
you take your Lamivudine/Zidovudine Teva.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:21.55pt;text-indent:-21.55pt;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>phenytoin</span></b><span
lang=EN-GB style='color:black'>, for treating <b>epilepsy.</b></span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><b><span
lang=EN-GB style='color:black'>Tell your doctor </span></b><span lang=EN-GB
style='color:black'>if you are taking phenytoin. Your doctor may need to
monitor you while you are taking Lamivudine/Zidovudine Teva.</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>medicines (usually liquids)
containing <b>sorbitol and other sugar alcohols</b> (such as xylitol, mannitol,
lactitol or maltitol), if taken regularly.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Tell your doctor</span></b><span lang=EN-GB
style='color:black'> or pharmacist if you are being treated with any of these.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Pregnancy </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>If you are pregnant, if you become pregnant or if you are
planning to become pregnant talk to your doctor about the risks and benefits to
you and your baby of taking Lamivudine/Zidovudine Teva.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lamivudine/Zidovudine Teva and similar medicines may cause
side effects in unborn babies. If you have taken Lamivudine/Zidovudine Teva
during your pregnancy, your doctor may request regular blood tests and other
diagnostic tests to monitor the development of your child. In children whose
mothers took NRTIs during pregnancy, the benefit from the protection against
HIV outweighed the risk of side effects.</span></p>

<p class=MsoNormal style='margin-right:-1.7pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Breast-feeding</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Women who are HIV-positive must not
breastfeed</span></b><b><span lang=EN-GB>,</span></b><span lang=EN-GB> because
HIV infection can be passed on to the baby in breast milk.</span></p>

<p class=MsoNormal><span lang=EN-GB>A small amount of<span style='color:#FF8100'>
</span>the ingredients in </span><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span lang=EN-GB> can also pass into your breast-milk.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you&#8217;re breast-feeding, or thinking
about breast-feeding:</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:.25in;line-height:normal'><b><span lang=EN-GB style='color:black'>Talk
to your doctor immediately.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Lamivudine/Zidovudine Teva can make you dizzy</span></b><span
lang=EN-GB style='color:black'> and have other side effects that make you less
alert.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:.25in;line-height:normal'><b><span lang=EN-GB style='color:black'>Do
not drive or operate machines</span></b><span lang=EN-GB style='color:black'>
unless you are feeling well</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Lamivudine/Zidovudine Teva</span></b><b><span lang=EN-GB> </span><span
lang=EN-GB>contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
&#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Always take this medicine exactly as
your doctor or pharmacist has told you. </span></b><span lang=EN-GB>Check with
your doctor or pharmacist if you are not sure. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Swallow Lamivudine/Zidovudine Teva tablets
with some water. Lamivudine/Zidovudine Teva can be taken with or without food. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you cannot swallow the tablet(s), you
may crush and combine them with a small amount of food or drink and take all
the dose immediately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Stay in regular contact with your doctor</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>Lamivudine/Zidovudine Teva helps to control your
condition. You need to keep taking it every day to stop your illness getting
worse. You may still develop other infections and illnesses linked to HIV
infection.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:.25in;line-height:normal'><b><span lang=EN-GB style='color:black'>Keep
in touch with your doctor, and do not stop taking Lamivudine/Zidovudine Teva </span></b><span
lang=EN-GB style='color:black'>without your doctor&#8217;s advice.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>How much to take</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><b><span lang=EN-GB
style='color:black'>Adults and adolescents 30&nbsp;kg or more</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><b><span lang=EN-GB
style='color:black'>The usual dose of Lamivudine/Zidovudine Teva is one tablet
twice a day.</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Take</span><span
lang=EN-GB style='color:black'> the </span><span lang=EN-GB style='color:black'>tablets
at regular times, leaving approximately 12 hours between each tablet.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><b><span lang=EN-GB
style='color:black'>Children who weigh between 21&nbsp;and 30&nbsp;kg</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The usual starting</span><span
lang=EN-GB style='color:black'> dose of Lamivudine/Zidovudine Teva is one</span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>half
tablet </span><span lang=EN-GB style='color:black'>(&frac12;) </span><span
lang=EN-GB style='color:black'>taken in the morning and one whole tablet taken
in the evening.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt'><b><span lang=EN-GB
style='color:black'>Children who weigh between</span><span lang=EN-GB
style='color:black'> 14</span></b><b><span lang=EN-GB style='color:black'> and</span><span
lang=EN-GB style='color:black'> 21&nbsp;kg</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The usual starting</span><span
lang=EN-GB style='color:black'> dose of Lamivudine/Zidovudine Teva is one</span><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>half
tablet </span><span lang=EN-GB style='color:black'>(&frac12;) </span><span
lang=EN-GB style='color:black'>taken </span><span lang=EN-GB style='color:black'>in
the morning and one half tablet (&frac12;) taken in the evening</span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For children </span><span
lang=EN-GB style='color:black'>who weigh</span><span lang=EN-GB
style='color:black'> less than 14&nbsp;kg lamivudine and zidovudine </span><span
lang=EN-GB style='color:black'>(</span><span lang=EN-GB style='color:black'>the
</span><span lang=EN-GB style='color:black'>ingredients</span><span lang=EN-GB
style='color:black'> of Lamivudine/Zidovudine Teva</span><span lang=EN-GB
style='color:black'>) should</span><span lang=EN-GB style='color:black'> be
taken </span><span lang=EN-GB style='color:black'>separately.</span><span
lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you take </span><span lang=EN-GB>more Lamivudine/Zidovudine Teva
than you should</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If you accidentally
take too much Lamivudine/Zidovudine Teva,</span><span lang=EN-GB
style='color:black'> tell your doctor or your pharmacist, or contact your
nearest hospital emergency department for further advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>If you forget to take a
dose, take </span><span lang=EN-GB style='color:black'>it</span><span
lang=EN-GB style='color:black'> as soon as you remember</span><span lang=EN-GB
style='color:black'>. Then</span><span lang=EN-GB style='color:black'> continue
</span><span lang=EN-GB style='color:black'>your treatment </span><span
lang=EN-GB style='color:black'>as before</span><span lang=EN-GB
style='color:black'>. Do not take a double dose to make up for a forgotten dose</span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, this medicine can cause
side effects, but not everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>During HIV therapy there may be an increase in
weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to the
HIV medicines themselves. Your doctor will test for these changes. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Treatment with Lamivudine/Zidovudine
Teva often causes a loss of fat from legs, arms and face (lipoatrophy). This
loss of body fat has been shown to be not fully reversible after discontinuation
of zidovudine. Your doctor should monitor for signs of lipoatrophy. Tell your
doctor if you notice any loss of fat from your legs, arms, and face. When these
signs occur, Lamivudine/Zidovudine Teva should be stopped and your HIV
treatment changed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>When </span><span lang=EN-GB style='color:black'>you are
being treated for</span><span lang=EN-GB style='color:black'> HIV, it </span><span
lang=EN-GB style='color:black'>can be hard </span><span lang=EN-GB
style='color:black'>to tell whether </span><span lang=EN-GB style='color:black'>a
symptom is a side effect of </span><span lang=EN-GB style='color:black'>Lamivudine/Zidovudine
Teva</span><span lang=EN-GB style='color:black'> or</span><span lang=EN-GB
style='color:black'> other medicines </span><span lang=EN-GB style='color:black'>you
are</span><span lang=EN-GB style='color:black'> taking</span><span lang=EN-GB
style='color:black'>,</span><span lang=EN-GB style='color:black'> or </span><span
lang=EN-GB style='color:black'>an effect of</span><span lang=EN-GB
style='color:black'> the HIV disease</span><span lang=EN-GB style='color:black'>
itself. <b>So</b></span><b><span lang=EN-GB style='color:black'> it is very
important </span></b><b><span lang=EN-GB style='color:black'>to talk to</span><span
lang=EN-GB style='color:black'> your doctor about any changes in your health.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>As well as the side effects listed below for
Lamivudine/Zidovudine Teva,</span><span lang=EN-GB style='color:black'> </span></b><span
lang=EN-GB style='color:black'>other </span><span lang=EN-GB style='color:black'>conditions
can develop during combination therapy for HIV. </span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB style='color:black'>It is important to read the information later in
this section under &#8216;Other possible side</span><span lang=EN-GB
style='color:black'> effects of </span><span lang=EN-GB style='color:black'>combination
therapy for HIV&#8217;.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very common side effects </span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>These may affect <b>more than 1</b> <b>in
10 </b>people: </span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>headache </span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>feeling sick (</span><i><span
lang=EN-GB style='color:black'>nausea</span></i><span lang=EN-GB
style='color:black'>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Common side effects </span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>These may affect <b>up to 1 in 10</b>
people:</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>being sick (<i>vomiting</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>stomach pains</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>loss of appetite</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>feeling dizzy</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>tiredness, </span><span
lang=EN-GB style='color:black'>lack of energy</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>fever (high temperature)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>general feeling of being
unwell</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>difficulty </span><span
lang=EN-GB style='color:black'>in </span><span lang=EN-GB style='color:black'>sleeping</span><span
lang=EN-GB style='color:black'> (<i>insomnia</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>muscle pain and discomfort</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>joint pain</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>cough</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>irritated or runny nose</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>skin rash</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>hair loss</span><span
lang=EN-GB style='color:black'> (<i>alopecia</i>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Common side effects that might show up in blood tests are:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>a </span><span lang=EN-GB
style='color:black'>low red blood cell count</span><span lang=EN-GB
style='color:black'> (<i>anaemia</i>) or </span><span lang=EN-GB
style='color:black'>low white blood cell count</span><span lang=EN-GB
style='color:black'> (<i>neutropenia </i>or<i> leucopenia</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>an increase in </span><span
lang=EN-GB style='color:black'>the </span><span lang=EN-GB style='color:black'>level
of liver enzymes</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>an increased amount in the</span><span
lang=EN-GB style='color:black'> blood </span><span lang=EN-GB style='color:
black'>of <i>bilirubin </i>(a substance produced in the liver) which may </span><span
lang=EN-GB style='color:black'>make </span><span lang=EN-GB style='color:black'>your
skin appear yellow.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Uncommon side effects </span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>These may affect <b>up to 1 in 100</b>
people:</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>feeling breathless</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>wind (<i>flatulence</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>itching</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>muscle weakness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>An uncommon side effect that may show up in blood test is:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>a decrease in the number of
cells involved in blood clotting (<i>thrombocytopenia</i>)<i> </i>or in all
kinds of blood cells (<i>pancytopenia</i>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rare side effects </span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>These may affect<b> up to 1 in 1000</b>
people:</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>serious allergic reaction
causing swelling of the face, tongue or throat which may cause difficulty in
swallowing or breathing</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>liver disorders</span><span
lang=EN-GB style='color:black'>,</span><span lang=EN-GB style='color:black'>
such as </span><span lang=EN-GB style='color:black'>jaundice, </span><span
lang=EN-GB style='color:black'>enlarged liver</span><span lang=EN-GB
style='color:black'> or</span><span lang=EN-GB style='color:black'> fatty
liver, inflammation (<i>hepatitis</i></span><span lang=EN-GB style='color:black'>)</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>lactic acidosis <i>(</i>excess
lactic acid in the blood; <i>see the next section, &#8216;Other possible side
effects of combination therapy for HIV&#8217;)</i></span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>inflammation of the pancreas</span><span
lang=EN-GB style='color:black'> (<i>pancreatitis</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>chest pain; disease of the
heart muscle (<i>cardiomyopathy</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>fits (<i>convulsions</i>)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>feeling depressed or
anxious, not being able</span><span lang=EN-GB style='color:black'> to
concentrate, feeling </span><span lang=EN-GB style='color:black'>drowsy</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>indigestion, taste
disturbance</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>changes in the colour of
your nails, your skin or the skin inside your mouth</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>a flu-like feeling &#8211;
chills and sweating</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>tingly feelings in the skin
(pins and needles)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>sensation of weakness in the
limbs</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>breakdown of muscle tissue</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>numbness</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>passing urine more often</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>enlarged breasts in men.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Rare side effects that may show up in blood tests are:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>an increase in an enzyme
called amylase</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>a failure of the bone marrow
to produce new red blood cells (<i>pure red cell aplasia</i>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Very rare side effects </span></p>

<p class=MsoNormal><i><u><span lang=EN-GB>These may affect <b>up to 1 in 10,000</b>
people</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>A very rare side effect that may show up in blood tests is:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>a failure of the bone marrow
to produce new red or white blood cells (<i>aplastic anaemia</i>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>If </span></b><b><span lang=EN-GB
style='color:black'>you get side effects</span></b></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:14.15pt;line-height:
normal'><b><span lang=EN-GB style='color:black'>Tell your doctor or pharmacist </span></b><span
lang=EN-GB style='color:black'>if </span><span lang=EN-GB style='color:black'>any
of the side effects </span><span lang=EN-GB style='color:black'>get severe or
troublesome</span><span lang=EN-GB style='color:black'>, or if you </span><span
lang=EN-GB style='color:black'>&nbsp; </span><span lang=EN-GB style='color:
black'>notice any side effects not listed in this leaflet.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Other possible side effects of combination therapy for HIV</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Combination therapy such as Lamivudine/Zidovudine Teva may
cause other conditions to develop during HIV treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Old infections may flare up</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>People with advanced HIV infection (AIDS) have weak immune
systems, and are more likely to develop serious infections (opportunistic
infections). When these people start treatment, they may find that old, hidden
infections flare up, causing signs and symptoms of inflammation. These symptoms
are probably caused by the body&#8217;s immune system becoming stronger, so
that the body starts to fight these infections.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>In addition to the opportunistic infections, autoimmune
disorders (a condition that occurs when the immune system attacks healthy body
tissue) may also occur after you start taking medicines for the treatment of
your HIV infection. Autoimmune disorders may occur many months after the start
of treatment. If you notice any symptoms of infection or other symptoms such as
muscle weakness, weakness beginning in the hands and feet and moving up towards
the trunk of the body, palpitations, tremor or hyperactivity, please inform
your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>If you get any symptoms of infection while you are
taking Lamivudine/Zidovudine Teva:</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:14.15pt;line-height:
normal'><b><span lang=EN-GB style='color:black'>Tell your doctor immediately. </span></b><span
lang=EN-GB style='color:black'>Do not take other medicines for the infection
without your &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; doctor&#8217;s advice.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Lactic acidosis is a rare but serious side
effect</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Some people taking Lamivudine/Zidovudine Teva develop a
condition called lactic acidosis, together with an enlarged liver.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Lactic acidosis is caused by a build up of lactic acid in
the body. It is rare; if it happens, it usually develops after a few months of
treatment. It can be life-threatening, causing failure of internal organs.
Lactic acidosis is more likely to develop in people who have liver disease, or
in obese (very overweight) people, especially women.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Signs of lactic acidosis include:</span></b></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>deep, rapid, difficult
breathing</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>drowsiness</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>numbness or weakness in the
limbs</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>feeling sick (nausea)<i>, </i>being
sick (vomiting)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>stomach pain.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>During your treatment, your doctor will monitor
you for signs of lactic acidosis. If you have any of the symptoms listed above,
or any other symptoms that worry you:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>See your doctor as soon as possible.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>You may have problems with your bones</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Some people taking combination therapy for HIV develop a
condition called osteonecrosis. With this condition, parts of the bone tissue
die because of reduced blood supply to the bone. People may be more likely to
get this condition:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if they have been taking
combination therapy for a long time</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if they are also taking
anti-inflammatory medicines called corticosteroids</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if they drink alcohol</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if their immune systems are
very weak</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if they are overweight.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>Signs of osteonecrosis include:</span></b></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>stiffness in the joints</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>aches and pains (especially
in the hip, knee or shoulder)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>difficulty moving.</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><span
lang=EN-GB style='color:black'>If you notice any of these symptoms:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Tell your doctor.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>Other effects may show up in blood tests</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Combination therapy for HIV can also cause:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>increased levels of lactic
acid in the blood, which on rare occasions can lead to lactic acidosis.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB> This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
Lamivudine/Zidovudine Teva</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the container or carton and blister after EXP. The expiry date refers to the
last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicinal product does not require any special storage
conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Do not throw away any medicines via waste water or
household waste. Ask your pharmacist how to throw away medicines you no longer use.
These measures will help to protect the environment.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB style='color:black'>Contents of the pack and other</span><span
lang=EN-GB> information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine/Zidovudine Teva contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substances are lamivudine 150&nbsp;mg
and zidovudine 300&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are: Tablet core:
Cellulose microcrystalline, sodium starch glycolate (Type A), sodium stearyl
fumarate. Tablet film-coat: Hypromellose 3cP, hypromellose 6cP, polysorbate 80,
macrogol 400, titanium dioxide E171.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Lamivudine/Zidovudine Teva looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>White, capsule shaped, biconvex, film-coated scored tablet &#8211;
engraved with &#8220;L/Z&#8221; on one side and &#8220;150/300&#8221; on the
other side.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The tablet is a breakable tablet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Lamivudine/Zidovudine Teva is available in aluminium blisters or
HDPE containers containing 60 tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Autnorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Teva B.V.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=DE>2031GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Teva Pharmaceutical Works Private Limited
Company</span></p>

<p class=MsoNormal><span lang=EN-GB>Pallagi &uacute;t 13</span></p>

<p class=MsoNormal><span lang=EN-GB>Debrecen</span><span lang=EN-GB> H-4042</span></p>

<p class=MsoNormal><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Pharmachemie B.V.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Swensweg 5</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2031 GA Haarlem</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Teva Operations Poland Sp. z.o.o.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=EN-GB>80 Mogilska St</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>31-546
Krakow</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>Poland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=DE>Merckle
GmbH</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=DE>Ludwig-Merckle-Strasse
3</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=DE>89143
Blaubeuren</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=535
 style='width:401.4pt;margin-left:9.0pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=DE>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Teva Pharma Belgium N.V./S.A./AG</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l/Tel: +32 38207373</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>UAB Teva Baltics</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +370 52660203</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='margin-right:28.35pt;line-height:normal;text-autospace:
  none'><span style='color:black'>&#1058;&#1077;&#1074;&#1072;</span><span
  style='color:black'> </span><span style='color:black'>&#1060;&#1072;&#1088;&#1084;&#1072;</span>
  <span lang=BG>&#1045;&#1040;&#1044;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Te</span><span
  lang=RU>&#1083;: +</span><span lang=BG>359 2</span><span lang=EN-GB>4899585</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Allemagne/Deutschland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l/Tel: +49 73140202</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Pharmaceuticals CR, s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +420 251007111</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Gy&oacute;gyszergy&aacute;r Zrt.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +36 12886400</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Denmark A/S</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tlf: +45 44985511</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>L-Irlanda</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +353 19127700</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>ratiopharm GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +49 73140202</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=DE>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Teva Nederland B.V.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +31 8000228400</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>UAB Teva Baltics Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +372 6610801</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Norway AS</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tlf: +47 66775590</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Specifar </span>A.B.E.E.</p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&#932;&#951;&#955;: +30 2118805000</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=DE>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>ratiopharm Arzneimittel Vertriebs-GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>Tel: +43 1970070</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Pharma, S.L.U.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +34 913873280</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PL>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PL>Teva Pharmaceuticals Polska Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +48 223459300</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Sant&eacute;</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>T&eacute;l: +33 155917800</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Pharma - Produtos Farmac&ecirc;uticos Lda.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: </span><span lang=EN-GB>+351 214767550</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Pliva Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +385 13720000</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Pharmaceuticals S.R.L.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +40 212306524</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Pharmaceuticals Ireland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +353 19127700</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Pliva Ljubljana d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +386 15890390</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Finnland</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>S&iacute;mi: +358 201805900</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>TEVA Pharmaceuticals Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +421 257267911</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Italia S.r.l.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +39 028917981</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Puh/Tel: +358 201805900</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'>Specifar
  A.B.E.E.</p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&#932;&#951;&#955;: +30 2118805000</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=PT-BR>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Teva Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>Tel: +46 42121100</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:40.65pt'>
  <td width=262 valign=top style='width:196.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>UAB Teva Baltics fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: </span><span lang=EN-GB>+371 67323666</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=274 valign=top style='width:2.85in;padding:0in 5.4pt 0in 5.4pt;
  height:40.65pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Teva UK Limited</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Tel: +44 1977628500</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b><span lang=EN-GB>{MM/YYYY}.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span><span lang=EN-GB><a href="http://www.emea.europa.eu">http://www.ema.europa.eu</a><span
style='color:blue'>/.</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
